Should You Buy La Rosa Holdings (LRHC) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
2.990
1 Day change
-5.38%
52 Week Range
396.000
Analysis Updated At
2026/01/30
LRHC is not a good buy right now for an impatient investor. Despite an extremely oversold RSI that can fuel sharp bounces, the broader trend is still bearish (SMA_200 > SMA_20 > SMA_5), Intellectia has no active buy signals, and the stock is in an event-heavy period (reverse split + big financing headline) that has recently produced erratic price moves (including a large post-market spike). I would stay on the sidelines until price action stabilizes above resistance and the trend structure improves.
Technical Analysis
Trend/structure: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) signals the primary trend is down.
Momentum: RSI_6 = 11.179 indicates extremely oversold conditions (bounce risk is high), but oversold alone is not a reliable buy trigger.
MACD: Histogram at 0.287 above zero but positively contracting suggests bullish momentum is fading rather than accelerating.
Key levels: Pivot 4.469. Near-term resistance R1 5.769 (then R2 6.571). Supports S1 3.169 and S2 2.367. With price ~5.524, it is sitting just below R1; failure to reclaim/hold above ~5.77 keeps downside risk elevated.
Pattern-based forecast (provided): ~80% chance of -0.95% next day, but +7.49% next week and +15.65% next month—i.e., near-term chop/down risk remains even if medium-term rebound odds improve.
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
could improve profitability if retention/volume hold.
can trigger sharp reflex rallies.
Neutral/Negative Catalysts
is typically associated with listing-compliance pressure and can weigh on sentiment.
Financial Performance
Latest quarter provided: 2025/Q3. Revenue increased to 20,216,143 (+3.18% YoY). Net income improved to -5,533,352 (loss narrowed, +64.09% YoY improvement). EPS dropped to -5.44 (-67.01% YoY), which is a notable negative on per-share performance. Gross margin improved to 8.45 (+1.20% YoY). Overall: modest revenue growth and better margins/loss improvement, but weak EPS dynamics suggest dilution/other per-share pressures.
Additional update: Preliminary FY2025 revenue ~ $79M (+14% YoY) supports a positive growth trend on a full-year basis.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target data was provided, so there is no observable recent trend in Wall Street rating or target changes. Based on the information available: Pros view would emphasize improving revenue growth (FY2025 +14% YoY), operational growth (agent/transactions), and the large financing catalyst. Cons view would focus on reverse-split-driven sentiment/credibility issues, ongoing losses and weak per-share results, and a still-bearish technical setup. Politicians/congress: No recent congress trading data available.
Wall Street analysts forecast LRHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRHC is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast LRHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LRHC is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
